Despite Advances in Precision Medicine, Disparities PersistNovember 23rd 2020
The goal of precision medicine is to advance medical and scientific discoveries while offering more tailored, precise, and accurate health interventions, thus maximizing health benefits for patients while reducing adverse effects and overall cost of care.
Overcoming Widespread Effects of COVID-19 Calls for Resilience, PerseveranceNovember 22nd 2020
The economic impact of the pandemic, which is still taking shape, will likely lead to many patients being uninsured, resulting in less access to medical care and ultimately culminating in an uptick in cancer-related mortality in the years ahead.
A Long-Term Survival Picture Emerges as Follow-up Data From NSCLC Trials MatureNovember 16th 2020
Dramatic improvements in efficacy outcomes for patients with non–small cell lung cancer have been a reason for celebration over the last decade, as FDA approvals of immunotherapy-plus-chemotherapy combinations as well as oncogenic-targeting drugs have transformed the treatment landscape.
Meeting Agenda Focuses on Increased Applications of Cellular Therapies in Hematologic CancersNovember 14th 2020
In an interview with Targeted Therapies in Oncology, Sagar Lonial, MD, detailed breakthroughs in the care of patients with multiple myeloma as well as other hematologic cancers, and offered a preview of what attendees might expect to hear at the 24th Annual International Congress on Hematologic Malignancies meeting.
Strength of Anti-HER2 Therapy Combination Is Further Validated in Asian PopulationNovember 14th 2020
Although the dual HER2 blockade combination is now considered a standard regimen for the treatment of patients with HER2-positive early-stage breast cancer, there are limited efficacy data regarding the use of the regimen in Asian populations.
A More Frequent Lanreotide Dose May Delay the Need for Other Therapies in NETsNovember 12th 2020
Results of the CLARINET FORTE study indicate that a dosing strategy of lanreotide given every 14 days may be a viable and safe option when the standard administration of every 28 days is not acceptable.
Hormone Receptor, pCR May Point to Survival on Dual HER2 BlockadeNovember 11th 2020
Updated data reported from a phase 3 trial show that patients with HER2- positive early breast cancer had better rates of overall survival after experiencing a pathologic complete response on HER2-targeted therapy, and these responses were observed most often in those with hormone receptor–negative status.